Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Market Reports
Enhancing clinical trial supply with JTM: part II
In a constantly changing world, the pharmaceutical industry is having to adopt its practices to serve the needs of a rapidly growing and ageing population and develop innovative personalised medicines. Almac has responded to these demands with a Just-in-Time Manufacturing solution that fulfils the requirements of a high value, time sensitive clinical supply chain. Dr Kevin Robinson spoke to Natalie Balanovsky, Just-in-Time Manufacturing Solutions Manager, and Mark Rohlfing, Vice President of Operations, to find out more
Next-generation pharmaceutical spray drying
Lonza's Kimberly B. Shepard, Associate Principal Engineer, and Michael M. Morgen, Associate Director, R&D, discuss mechanistic process development with high-performance polymers for bioavailability enhancement
Reading and understanding vendor-supplied tablet drawings
Understanding the tablet drawings supplied by tooling vendors is a meaningful way to learn more about your product, reports John Norman, Technical Service Representative, Natoli Engineering Company
Lessons from a modern-day pandemic: redesigning the pharmaceutical supply chain
The pharmaceutical industry has responded extremely well to the coronavirus pandemic. At the same time, the industry is changing before our eyes. To put it in simple terms, there will be no more “business-as-usual” in pharmaceutical manufacturing after COVID-19, explains Andrew Badrot, CEO, C2 PHARMA
A pivotal time for pharma's global biotechnology industry
In these uncertain times, GEA, the globally active mechanical and plant engineering company, is taking its role in the fight against the coronavirus — and any other — epidemic, extremely seriously. Committed to “Engineering for a better world,” GEA designs and builds modular plant and fully integrated systems help to bring new treatments to market in the shortest possible time
Accelerating vaccine development with AI
Despite the tremendous advances in medical science in recent decades, there is still so much about the human body that we’re yet to discover, reports Billy Sisk, Life Sciences Industry Manager, EMEA, Rockwell Automation
How to comply with FDA-imposed nitrosamine impurity testing
The detection of nitrosamine impurities in commercially available drugs has recently prompted the US FDA to issue multiple product recalls and mandate additional testing to safeguard consumer health and safety; Michael Walker, Technical Expert at Intertek Pharmaceutical Services, and Jon Bardsley, Vertical Marketing Specialist, Pharma and BioPharma, Thermo Fisher Scientific, report
Excipient innovation for enhanced patient compliance: part II
Formulation can be challenging, particularly when working with excipients such as sugar alcohols. However, a new line extension from SPI Pharma offers a solution that leverages the patient-centric benefits of mannitol while avoiding common drug development problems and simplifying manufacturing
Future-proof DMPK studies for next-generation therapeutics
SCIEX's Lei Xiong, Rolf Kern and Elliott Jones explain the top five reasons why you can’t count on ligand-binding assays to study the drug metabolism and pharmacokinetics of biologics
Tackling coronavirus with AI-derived combination drug products: Part I
The ongoing spread of COVID-19 is risking the lives of millions of rare disease patients around the world. Dr David Brown, Chairman and cofounder of Healx, believes the company’s data-driven AI platform is perfectly positioned to support the efforts to find effective treatments and, within weeks, predict which known drugs can be repurposed to treat other conditions
New date announced for Manufacturing Chemist Live
The inaugural conference will now take place on 28-29 October 2020
Excipient innovation for enhanced patient compliance: part I
Formulation can be challenging, particularly when working with excipients such as sugar alcohols. However, a new line extension from SPI Pharma offers a solution that leverages the patient-centric benefits of mannitol while avoiding common drug development problems and simplifying manufacturing
Sustainability and innovation in the complex combination therapy sector
The patient and commercial benefits of bringing new drugs to market in the shortest possible time are well recognised; potential methodologies to reduce the development cycle and accelerate drug product approvals are constantly being explored. As a result, other targets, including the environmental efficacy of a therapy, have traditionally been a distant, secondary objective. Bespak's Jay Bhogaita, Business Director, reports
Delivering certainty in uncertain times
Contract manufacturing organisations (CMOs) in the pharmaceutical sector operate at the sharp end of an industry in which one mistake or delay could be serious or even fatal. Rodney Steel, CEO of the British Contract Manufacturers and Packers Association (BCMPA), discovers how CMOs have become experts in predicting the future, ensuring that nothing is left to chance
Service in times of bits and bytes
Whoever talks to the service experts at Syntegon Technology, formerly Bosch Packaging Technology, communicates both digitally and globally. The shift from analogue to bits and bytes has not only changed communication between service employees and customers. In the course of digitisation, the company has modernised and expanded its entire service portfolio — and has reinvented itself to a certain extent
How AI will disrupt drug development
In the last 4–6 years, companies have been experimenting with new approaches that utilise the latest in artificial intelligence (AI) and machine learning technologies to identify new molecules and validate new drugs faster and more efficiently. Egor Kobelev, VP of Healthcare and Life Sciences at DataArt, examines some of the ways these breakthroughs are transforming drug discovery
Opening the aperture: taking a wider view of the inhalables market
With a new company strategy in place and a combined focus on both drug and device development, Dr Kevin Robinson spoke to Vectura’s new CEO and Executive Director, Will Downie, about the current and future market for inhaled therapies
Rethinking HPLC degassing with novel flat film technology
During the first three decades of liquid chromatography (LC) use, outgassing in the mobile phase was a key challenge in routine LC workflows. However, since the emergence of online degassers in the 1970s, these devices have become an ordinary component of most LC systems and, therefore, their development is often overlooked
Expanding globally: building on a European presence
To build the overseas presence of Federal Equipment Company and solidify our status as a global provider of equipment solutions, we have opened an office in the Netherlands, reports Paul Sombekke, European Business Development Manager
Granulation: an established technology in a changing world
Optimising the granulation process — the most important unit operation during the production of pharmaceutical oral solid dosage forms — is not only a critical aspect of operational excellence, it also plays a major role in preventing downstream compression problems
John Baker: life sciences need to address the reproducibility crisis
The head of product innovation at Abcam says it is crucial that the whole industry finds ways to de-risk the route to the patient as early as possible
Optimise desiccants with 3D validation software
Baltimore's CFD model brings predictive science to validation. Desiccants are tested for performance over time, bringing cost-efficiency to the forefront. Dr Mark Valentine explains
IntelGenx: oral films are drug development’s patent trick
Exploiting improvements in bioavailability, the Canadian company has developed unique oral film technology to help drugmakers secure exclusivity and financial returns
How to avoid sticking and picking in the tableting industry
John Norman and Kevin Queensen of Natoli Engineering explain
Previous
1
2
3
4
(current)
5
6
7
8
9
Next
Trending Articles
Drug dose delivery development, manufacturing and commercialisation trends: part II
In the wake of patient-centricity in the pharmaceutical industry, drug delivery technologies have emerged as a central driver of therapeutic and patient success. Dr Kevin Robinson went online with Manuel Leal, Business Development Director, Idifarma, Steve Rode, Manager Business Development, Capsules and Health Ingredients, Lonza, and John Ross, President, Mayne Pharma US/Metrics Contract Services, to find out more
How to avoid sticking and picking in the tableting industry
John Norman and Kevin Queensen of Natoli Engineering explain
Adding more to the cell and gene therapy playbook
With notable advances in various forms of administration, including making the use of viral vectors safer, non-viral delivery with lipid nanoparticles and the growing application of electroporation, Dr Kevin Robinson (KSR) recently caught up with Jason Potter (JP), Director of Cell Biology R&D at Thermo Fisher Scientific, to learn more about how the company is helping the pharmaceutical industry to develop cell and gene therapies
How to proactively address EU HTAR implementation challenges before 2025
Data landscape challenges within the European Union (EU) have historically been driven by the different laws, processes and regulatory standards of its 27 member states (MS). As a result, drug therapeutics and health technology developers have faced the challenge of duplication of assessment efforts
Highly potent formulation development in oncology
Formulation development is a dynamic and experimental process. However, certain challenges are presented to CDMOs that add a layer of unnecessary pressure to the development process — some of which are avoidable. Louise Carpenter from PCI Pharma Services discusses
Upcoming event
BIO International Convention Digital
3-6 June, 2024 | Convention | San Diego, US
See all